Medically Reviewed By: Dr. Imran Khan, MD, IFMCP

Last Medically Reviewed: October 19, 2026

Compare the Method and the Specific Test

Functional chemo-sensitivity testing describes an approach: observing how patient-derived cancer cells respond to drugs in a laboratory. RGCC is a laboratory provider whose panels may include drug-response analysis as well as circulating tumor cell measurements. The categories overlap, so a useful comparison identifies the specific assay, sample, question, and evidence.

Understanding these differences can help patients discuss additional testing options and their limitations with their oncology team.

A conceptual diagram showing the interconnected web of gut, immune, and metabolic health.

Disclaimer: This information is for educational purposes only and is not intended as medical advice. It does not replace, delay, or substitute for standard oncology care, screening, diagnosis, or treatment recommended by your oncology team.

What Is Functional Chemo-Sensitivity Testing?

Functional chemo-sensitivity testing examines how living cancer cells respond to selected chemotherapy drugs under controlled laboratory conditions. Depending on the assay, the cells may come from fresh tumor tissue or a blood sample; confirm the selected laboratory’s requirements.

Unlike genomic testing, which examines molecular changes, functional testing observes cellular responses after drug exposure. These findings may indicate laboratory sensitivity or resistance but cannot reliably predict treatment outcomes.

What Functional Chemo-Sensitivity Testing Measures

Depending on the assay, functional testing may evaluate:

  • Drug sensitivity: Changes in tumor cell survival following chemotherapy exposure.
  • Cellular response: Changes in cell growth, viability, or cell death.
  • Resistance patterns: Reduced laboratory responses to selected drugs.

The American Society of Clinical Oncology's (ASCO) 2011 guideline update does not recommend using chemotherapy sensitivity and resistance assays to select treatment outside clinical trials because sufficient evidence of clinical benefit has not been established.

What Is RGCC Cancer Testing?

Research Genetic Cancer Centre (RGCC) develops laboratory tests that examine circulating tumor cells (CTCs) and related cancer characteristics.

Depending on the panel, RGCC testing may assess CTC counts, cellular markers, or laboratory responses to selected drugs and substances. Many panels use blood samples, with findings that require interpretation alongside established oncology assessments.

Understanding Circulating Tumor Cells (CTCs)

Circulating tumor cells are cancer cells that have separated from a tumor and entered the bloodstream.

According to the National Cancer Institute, CTCs may serve as biomarkers in certain cancer settings, including treatment planning or prognosis.

However, not all cancers release detectable CTCs. Their significance varies by cancer type and testing method, and CTC findings alone cannot confirm or rule out cancer.

How Are Cancer Stem Cells Different From CTCs?

Cancer stem cells (CSCs) are tumor cells studied for their ability to renew themselves and generate other tumor cells. CTCs, meanwhile, are identified by their presence in the bloodstream.

CTC and CSC describe different properties: location in the bloodstream versus self-renewal. RGCC’s Oncotrace measures stemness markers, but marker findings alone do not prove that a cell is a cancer stem cell or establish cancer progression or treatment success.

Understanding the Different RGCC Testing Options

IHAWMD’s RGCC Testing page describes four panels with different laboratory purposes. Sample requirements vary by panel and cancer type; RGCC’s Onconomics Plus documentation lists blood or tissue, with tissue specified for primary central nervous system tumors.

Oncotrace

Oncotrace evaluates CTC counts, cellular phenotype markers, and markers associated with stem-like characteristics.

These findings may provide additional information for monitoring discussions but cannot independently confirm cancer progression or recurrence.

Onconomics

Onconomics evaluates laboratory responses of cancer-related cells to selected therapeutic agents, including sensitivity or resistance patterns.

Results may inform discussions about testing options but cannot establish which treatment will work for an individual patient.

Onconomics Plus

Onconomics Plus examines laboratory responses to selected anticancer drugs, targeted therapies, and natural substances.

The results provide laboratory sensitivity or resistance information but do not establish treatment effectiveness or safety in patients.

Onconomics Extracts+

Onconomics Extracts+ assesses laboratory responses to selected natural substances and plant extracts.

These findings do not demonstrate that natural substances can treat cancer in humans. Natural products may interact with prescribed therapies and should not replace recommended treatment.

Compare Assays, Samples, and Results

Both approaches examine cancer-related biological activity, but their methods and intended applications differ.

Sample Types and Testing Methods

Functional drug-response assays can use viable tissue-derived or blood-derived cells. Datar’s ChemoScale describes both routes, so tissue versus blood alone does not distinguish functional testing from RGCC.

RGCC’s sample requirements depend on the panel and cancer type. Compare the actual assay protocols rather than assuming every RGCC test is blood-only.

Information Provided by Each Test

Functional testing focuses on tumor cell responses to chemotherapy outside the body.

RGCC testing may provide CTC counts, cellular characteristics, and drug-response findings, depending on the panel.

Neither approach independently establishes clinical treatment effectiveness, and results require interpretation alongside established diagnostic information.

Why Laboratory Results Are Not Interchangeable

Assays from different laboratory providers may use different sample-processing procedures, analyses, and reporting methods.

An existing report from another provider may inform a physician’s broader assessment, but it does not automatically replace the sample or analysis required for a specific RGCC test. Confirm what the ordering laboratory accepts before arranging testing.

Each test must be interpreted according to its methodology and intended purpose. These differences do not establish that one approach is inherently superior.

Review Results Alongside Oncology Findings

Advanced testing results may be reviewed alongside established clinical findings, including:

  • Confirmed cancer diagnosis, type, and stage.
  • Pathology, imaging, and guideline-recommended molecular testing.
  • Current treatment, previous responses, and overall health.
  • Test-specific limitations and available clinical evidence.

An important consideration is whether additional results would meaningfully inform the patient's care.

Experimental or insufficiently validated test findings should not independently determine whether cancer treatment is selected, changed, or delayed.

Questions to Ask Before Choosing a Test

The value of additional cancer testing depends on the patient's diagnosis, available samples, clinical circumstances, and the specific question being evaluated.

Discussing Functional Drug-Response Testing

Discuss whether suitable tissue-derived or blood-derived cells are available and what additional laboratory question the assay would address. Ask whether the specific test has demonstrated clinical utility for the cancer type and whether a clinical trial is appropriate.

Discussing a Specific RGCC Panel

RGCC testing may be discussed when a patient and physician are considering additional CTC-related information or another analysis offered by a specific panel.

Before ordering, patients should understand the test's purpose, evidence, limitations, and potential relevance to their oncology care.

IHAWMD's Approach to Personalized Cancer Testing

At Internal Healing and Wellness MD, Dr. Imran Khan and the clinical team consider advanced testing within a broader functional and integrative medicine approach.

Physician-Guided Test Evaluation

Testing discussions consider the patient's medical history, confirmed diagnosis, treatment plan, and clinical questions to determine whether additional evaluation may be appropriate.

A Broader View of Patient Health

IHAWMD considers nutrition, metabolic health, and overall wellness alongside established medical needs, without replacing cancer-directed treatment.

Coordination With Oncology Care

Additional findings should be interpreted alongside pathology, imaging, and oncology recommendations. Patients are encouraged to discuss testing and treatment decisions with their treating oncologist.

Conclusion

The most useful comparison starts with a specific test, not a broad label. Ask which laboratory will run the assay, what it measures, and whether its evidence fits your clinical question. IHAWMD can help you understand these choices in the context of your health history and ongoing oncology care.

Discuss Personalized Cancer Testing With IHAWMD

If you are considering functional chemo-sensitivity or RGCC cancer testing in The Woodlands, Houston, or surrounding Greater Houston communities, request a cancer testing consultation with IHAWMD.

Our team can review your medical history, current care plan, and whether additional testing warrants discussion with your oncology team.

Frequently Asked Questions

Do not assume that an RGCC test is FDA-approved or cleared for cancer screening. Ask your clinician to verify the regulatory status and intended use of the specific assay being considered. RGCC testing does not replace recommended cancer screening.

RGCC tests may analyze CTCs and related markers, but their findings cannot independently confirm or rule out cancer. Diagnosis requires appropriate medical evaluation, which may include imaging, biopsy, and pathology.

Functional testing is an approach to measuring drug responses outside the body. RGCC is a provider offering several analyses, including CTC measurements and selected drug-response assays; compare the specific tests rather than treating the categories as mutually exclusive.

No. Laboratory sensitivity findings cannot reliably predict clinical treatment success. Treatment decisions should follow evidence-based oncology recommendations.

Other laboratory reports may provide clinical context, but they do not automatically replace RGCC’s required analysis. The ordering laboratory should confirm which samples and reports are acceptable.

Relevant Studies and References